Abstract
A VARIETY of antisickling substances, both synthetic and naturally occurring, have been studied for their potential value as agents for the treatment of sickle cell disease. 3,4-dihydro-2, 2-dimethyl-2H-l-benzopyran-6-butyric acid (DBA), a chemically modified derivative of xanthoxylol isolated from Fagara zanthoxyloides, has been reported to prevent as well as reverse sickling of sickle cell anaemia erythrocytes1. 10 mM DBA was described as being able virtually to abolish sickling within a period of 30 min1. We have examined the effect of DBA on washed erythrocytes prepared from blood of sickle cell anaemia patients, and report here that we have been unable to demonstrate any antisickling effect of DBA.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ekong, D. E. U. et al. Nature 258, 743 (1975).
Honig, G. R., Farnsworth, N. R., Ferenc, C. & Vida, L. N. Lloydia 38, 387 (1975).
Elbaum, D., Nagel, R. L., Bookchin, R. M. & Herskovits, T. T. Proc. natn. Acad. Sci. U.S.A. 71, 4718 (1974).
Bertles, J. F., Dobler, J. Blood 33, 884 (1969).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
HONIG, G., VIDA, L. & FERENC, C. Effects in vitro of the proposed antisickling agent DBA. Nature 272, 833–834 (1978). https://doi.org/10.1038/272833a0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/272833a0
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
